EPFL spin-off Abionic poised to break into the US market
(WorldNews Switzerland)

20.10.17- The United States Food and Drug Administration has just registered Abionic`s rapid allergy diagnostic system, which tests for sensitivity to four common respiratory allergens in the United States. This puts the EPFL spin-off on track to market its single-use capsules and testing platform in the US in 2018. It takes only five minutes and a single drop of blood for Abionic`s abioSCOPE to...